Regencell Bioscience Holdings Limited Announces Registered Direct Offering of Ordinary Shares

Regencell Bioscience Holdings Limited (Nasdaq: RGC) has entered into a definitive agreement for a registered direct offering of 985,222 ordinary shares at $20.30 per share. The offering is expected to yield approximately $20.0 million in gross proceeds, with a significant $19 million investment from a new institutional investor and participation from Univest Securities, LLC. This offering is being made under a previously filed shelf registration statement on Form F-3. The transaction is anticipated to close around May 20, 2026, subject to standard closing conditions. Univest Securities, LLC is serving as the sole placement agent for this offering. This report also incorporates by reference the company's registration statement filed on March 30, 2026, and includes exhibits such as legal opinions regarding Cayman Islands tax matters and forms of the securities purchase and placement agent agreements.